Abstract Details

Title Biochemical Aspirin Resistance and Clinical Outcome in Indian Patients with Ischemic Stroke

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S53 - Stroke Prevention (4:42 PM-4:54 PM)

Poster/Presentation
Number 007

Objective To estimate the prevalence of biochemical aspirin resistance and its association with clinical outcomes among patients with ischemic stroke.

Background Aspirin is the most frequently used antiplatelet agent in secondary stroke prevention after an ischemic stroke. However, some patients may have an incomplete response to the antithrombotic action of aspirin

Design/Methods This is a cross sectional, prospective cohort study at the All India Institute of Medical Sciences, New Delhi, India. Patients with a recent ischemic stroke receiving only aspirin as an antiplatelet agent, for at least 7 days and within 30 days of the stroke event were enrolled in the study. Aspirin responsiveness was determined by Light Transmission Aggregometry (LTA). Patients were classified into aspirin resistant, aspirin semi-resistant and aspirin sensitive group using standard definitions. Clinical outcome was measured using modified Ranking Score (mRS) at 3 months and 12 months and recurrence of stroke at one year

Results

This is an interim analysis from an ongoing study. Data of 304 patients is presented. There were 215 (70.72%) males and 89 (29.28%) females with a of 54.50 ± 14.53 years. 30 (9.90%) patients were resistant to aspirin; 84 (27.74%) patients were semi- resistance to aspirin; 189 (62.38%) patients were sensitive to aspirin.3 months and 12 months follow up was completed for 254 and 194 patients respectively. Higher proportion of patients in the aspirin sensitive group had a good outcome (mRS 0-2) at 3 months (p value=0.024 ) and at 12 months (p value=0.009). The mortality rate was also statistically higher in the aspirin resistance group at 3 months (p=0.002) and 12 months (p value=0.031) Recurrence of stroke was higher in aspirin resistance group than aspirin sensitive group, (p value= 0.006)

Conclusions

Biochemical aspirin resistance is not uncommon in ischemic stroke patients and is associated with poorer outcome, higher mortality and recurrence of stroke.

Authors/Disclosures
Rohit Bhatia, MD, MBBS, DM PRESENTER	Dr. Bhatia has nothing to disclose.
	No disclosure on file
M.V.Padma Srivastava	No disclosure on file
	No disclosure on file
	No disclosure on file
Kameshwar Prasad, MD (Rajendra Institute of Medical Sciences, Ranchi)	The institution of Prof. Prasad has received research support from Government of India Departments of Health Research and Biotechnology.
	No disclosure on file
Mamta B. Singh, MD, MBBS, DM, FAAN (All India Institute of Medical Sciences)	Dr. Singh has nothing to disclose.

��ɫ��

��ɫ��